MS Care in Novel Coronavirus 19 Pandemic

Neda Ramezani, Iman Adibi, Omid Mirmosayyeb, Vahid Shaygannejad

Abstract


One hundred years after the influenza outbreak in 1918 coronavirus disease (COVID‑19) became a global health issue, which forces us to adapt our professional customs in the health care system. Our recent practice, since the
1990s, of processing experimental and observational evidences and time‑consuming methods of developing guidelines seem not to be efficient enough because of scarce evidence and rapidly spreading disease. According
to formal announcements, until writing this letter, we had more than 95,000 COVID‑19 patients in Iran with a mortality rate of 6.3%.

Keywords


Multiple Sclerosis; Care; Pandemics; COVID-19

Full Text:

PDF

References


World Health Organization. Coronavirus disease (COVID‑19)

outbreak. 2020.

Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O.

Treating multiple sclerosis and neuromyelitis optica spectrum

disorder during the COVID‑19 pandemic. Neurology 2020. doi:

1212/WNL.0000000000009507.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al.

Pathological findings of COVID‑19 associated with acute

respiratory distress syndrome. Lancet Respir Med 2020;8:420‑2.

Giovannoni G, Hawkes C, Lechner‑Scott J, Levy M, Waubant E, Gold J. The COVID‑19 pandemic and the use of

MS disease‑modifying therapies. Mult SclerRelat Disorder

;39:102073.

Lythgoe MP, Middleton P. Ongoing Clinical Trials for the

Management of the COVID-19 Pandemic. Trends Pharmacol Sci

;41:363-82.